| Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure. A Randomised Double-blind Placebo-controlled International Multicenter Study. |
Terminated |
Ivabradine |
3 |
CL3-16257-083 |
King Fahad Medical City (Riyadh) |
| A Randomized Study of the Effect of Maintenance Therapy With Bevacizumab + Capecitabine Versus Bevacizumab Alone on Progression-free Survival in Patients With HER2-negative Metastatic Breast Cancer That Has Not Progressed During First-line Docetaxel Plus Bevacizumab Therapy |
Terminated |
Bevacizumab+ Capecitabine |
3 |
MO22223 |
King Abdulaziz Hospital and Oncology Center (Jeddah), King Abdulaziz Medical City NG (Riyadh), King Fahad Specialist Hospital (Dammam) |
| An open-Label, multicenter, expanded access study of Everolimus in Patients with advanced Nerouendocrine tumors. |
Completed |
Everolimus |
3b |
CRAD001K24133 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase 3b, open-labeled, randomized, parallel-group, multi-center study to evaluate the safety of novartis MenACWY Conjugate Vaccine when administered with routine infant Vaccinations to healthy Infants |
Completed |
Meningococcal ACWY Conjugate Vaccine |
3b |
V59P23 |
King Fahad Medical City (Riyadh) |
| Extending molecular responeses with Nilotinib in newly diagnosed chronic myeloid leukemia (CML) patients in chronic phase (ENESTxtnd) |
Completed |
Nilotinib |
3b |
CAMN107E2401 |
King Fahad Specialist Hospital (Dammam), King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah), King Abdulaziz Medical City NG (Jeddah), King Abdulaziz Hospital and Oncology Center (Jeddah) |
| An Open-lable, Randomized, Multi center, Phase III Study to Compare the Saftey and Efficacy of TKI258 Versus Sorafenib in Patients with Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor Therapies" |
Completed |
TKI258 / Sorafenib |
3 |
CTKI258A2302 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma (DESTINATION) |
Ongoing |
Tezepelumab |
3 |
D5180C00018 |
King Abdulaziz University Hospital (Jeddah), King Abdulaziz Medical City NG (Riyadh) |
| Comparison of the Efficacy and Safety for different regimen of Venous Thromboembolism pharmacoprophylaxis among Severely Burn Patients: A Multicenter, Randomized Controlled Trial |
Ongoing |
HEPARIN SODIUM, ENOXAPARIN SODIUM |
4 |
RC18/400/R |
King Abdulaziz Medical City NG (Riyadh) |
| Psoriasis Study of Health Outcomes (PSoHO) – an International Observational Study of 3-Year Health Outcomes in the Biologic Treatment of Moderate-to-Severe Plaque Psoriasis |
Ongoing |
Any biologic therapy (including biosimilars) available on the market and prescribe to patients within routine care |
4 |
1F-MC-B007 |
Hira Hospital (Makkah) |
| Randomized, double blind, placebo controlled study to evaluate the effect of dupilumab on airway inflammation through assessments of lung function, mucus plugging and other lung imaging parameters in patients with asthma |
Ongoing |
DUPILUMAB |
4 |
LPS15834 |
King Fahad Medical City (Riyadh) |
